Pharmacologic treatment of neuropsychiatric disorders. 1993

J M Silver, and S C Yudofsky
Neuropsychiatry, Columbia-Presbyterian Medical Center; and Clinical Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY.

Emotional and cognitive symptomatologies, such as depression, mania, lability of mood and affect, psychosis, impaired arousal, anxiety, and irritability and aggression often occur in neurologic disorders. These neuropsychiatric syndromes significantly impair functioning and efforts at rehabilitation. Patients with brain damage are especially sensitive to the side effects of medication. When appropriate guidelines are followed, psychopharmacologic intervention alleviates these symptoms, enhances rehabilitation, and avoids impairment of arousal and cognition.

UI MeSH Term Description Entries

Related Publications

J M Silver, and S C Yudofsky
October 2000, Seminars in clinical neuropsychiatry,
J M Silver, and S C Yudofsky
January 2000, Child and adolescent psychiatric clinics of North America,
J M Silver, and S C Yudofsky
December 1984, The Psychiatric clinics of North America,
J M Silver, and S C Yudofsky
April 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
J M Silver, and S C Yudofsky
June 2019, The Psychiatric clinics of North America,
J M Silver, and S C Yudofsky
September 1986, The Journal of clinical psychiatry,
J M Silver, and S C Yudofsky
December 1982, The Journal of clinical psychiatry,
J M Silver, and S C Yudofsky
January 2016, Expert review of clinical pharmacology,
J M Silver, and S C Yudofsky
January 2010, Annual review of medicine,
Copied contents to your clipboard!